Efficacy and safety of FLAG-IDA as front-line therapy in de novo paediatric acute myeloid leukaemia population.
作者信息
Doan Andrew, Huang Holly K T, Hadar Ari J, Malvar Jemily, Rushing Teresa, Raca Gordana, Kovach Alexandra E, Freyer David R, Parekh Chintan, Stokke Jamie, Posch Leila C, Dao Julie, Bhojwani Deepa, Gaynon Paul, Orgel Etan
机构信息
Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, California, USA.
出版信息
Br J Haematol. 2023 Jul;202(1):e3-e6. doi: 10.1111/bjh.18844. Epub 2023 May 2.
Abstract
摘要
相似文献
1
Efficacy and safety of FLAG-IDA as front-line therapy in de novo paediatric acute myeloid leukaemia population.FLAG-IDA作为初治儿童急性髓系白血病一线治疗方案的疗效和安全性
Br J Haematol. 2023 Jul;202(1):e3-e6. doi: 10.1111/bjh.18844. Epub 2023 May 2.
2
Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.氟达拉滨、阿糖胞苷、粒细胞集落刺激因子和伊达比星（FLAG-IDA）治疗预后不良的儿童急性白血病：哈杰泰佩大学的经验
Pediatr Hematol Oncol. 2010 Oct;27(7):517-28. doi: 10.3109/08880018.2010.493578.
3
Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.氟达拉滨、阿糖胞苷、粒细胞集落刺激因子和伊达比星用于复发性儿童急性髓系白血病
Pediatr Int. 2017 Oct;59(10):1046-1052. doi: 10.1111/ped.13378.
4
A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial.FLAG-伊达比星与柔红霉素联合氯法拉滨治疗高危急性髓系白血病的比较：来自英国国家癌症研究所AML17试验的数据。
Leukemia. 2018 Dec;32(12):2693-2697. doi: 10.1038/s41375-018-0148-3. Epub 2018 Jun 6.
5
FLAG-Ida Regimen as Bridge Therapy to Allotransplantation in Refractory/Relapsed Acute Myeloid Leukemia Patients.FLAG-伊达比星方案作为难治性/复发性急性髓系白血病患者异基因移植的桥接治疗
Clin Lymphoma Myeloma Leuk. 2017 Nov;17(11):767-773. doi: 10.1016/j.clml.2017.06.002. Epub 2017 Jun 19.
6
[IDA-FLAG regimen in treatment of patients with refractory or relapsed acute leukemia].伊达比星-氟达拉滨方案治疗难治性或复发性急性白血病
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Apr;17(2):464-7.
7
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With and Mutations.氟达拉滨、阿糖胞苷、粒细胞集落刺激因子和伊达比星联合吉妥珠单抗奥佐米星可改善新诊断的 AML 年轻患者的无事件生存和 和 突变患者的总生存。
J Clin Oncol. 2024 Apr 1;42(10):1158-1168. doi: 10.1200/JCO.23.00943. Epub 2024 Jan 12.
8
The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia.复发或难治性急性髓系白血病患者接受不含去甲氧柔红霉素的FLAG化疗的临床结局。
J Korean Med Sci. 2009 Jun;24(3):498-503. doi: 10.3346/jkms.2009.24.3.498. Epub 2009 Jun 15.
9
FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.FLAG-IDA方案治疗难治性/复发性急性白血病：单中心研究
J Pak Med Assoc. 2005 Jun;55(6):234-8.
10
FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemia.FLAG 挽救疗法联合伊达比星治疗复发/难治性急性髓系白血病。
Leuk Lymphoma. 2019 Apr;60(4):1014-1022. doi: 10.1080/10428194.2018.1508670. Epub 2018 Oct 2.
引用本文的文献
1
Impact of Molecular and Cytogenetic Responses on Long-Term Outcomes in Children and Adolescents With Chronic Myeloid Leukemia: A Retrospective Study From India.分子和细胞遗传学反应对慢性髓性白血病儿童和青少年长期预后的影响：一项来自印度的回顾性研究
Cureus. 2025 Aug 4;17(8):e89359. doi: 10.7759/cureus.89359. eCollection 2025 Aug.
本文引用的文献
1
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.2021 年急性髓系白血病微小残留病更新：来自欧洲白血病网微小残留病工作组的共识文件。
Blood. 2021 Dec 30;138(26):2753-2767. doi: 10.1182/blood.2021013626.
2
Health-Related and Economic Burden Among Family Caregivers of Patients with Acute Myeloid Leukemia or Hematological Malignancies.急性髓系白血病或血液系统恶性肿瘤患者的家庭照料者的健康相关和经济负担。
Adv Ther. 2021 Oct;38(10):5002-5024. doi: 10.1007/s12325-021-01872-x. Epub 2021 Sep 9.
3
Treatment of acute myeloid leukemia in children: A practical perspective.儿童急性髓系白血病的治疗：实用观点。
Pediatr Blood Cancer. 2021 Jul;68(7):e28979. doi: 10.1002/pbc.28979. Epub 2021 Apr 12.
4
A multimodal genomics approach to diagnostic evaluation of pediatric hematologic malignancies.一种多模态基因组学方法用于儿科血液系统恶性肿瘤的诊断评估。
Cancer Genet. 2021 Jun;254-255:25-33. doi: 10.1016/j.cancergen.2021.01.007. Epub 2021 Jan 21.
5
Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group.硼替佐米联合标准化疗方案治疗儿童急性髓系白血病并未改善治疗结局：来自儿童肿瘤协作组的报告。
Haematologica. 2020 Jul;105(7):1879-1886. doi: 10.3324/haematol.2019.220962. Epub 2020 Feb 6.
6
Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity.蒽环类和蒽醌等效比推导至多柔比星用于迟发性心脏毒性。
JAMA Oncol. 2019 Jun 1;5(6):864-871. doi: 10.1001/jamaoncol.2018.6634.
7
Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children's Oncology Group.在 AAML0531 临床试验中接受治疗的儿童中治疗相关心脏毒性的发生及其对结局的影响：来自儿童肿瘤学组的报告。
J Clin Oncol. 2019 Jan 1;37(1):12-21. doi: 10.1200/JCO.18.00313. Epub 2018 Oct 31.
8
Cardiac function in survivors of childhood acute myeloid leukemia treated with chemotherapy only: a NOPHO-AML study.仅接受化疗的儿童急性髓系白血病幸存者的心脏功能：一项北欧儿童血液肿瘤学会-急性髓系白血病研究
Eur J Haematol. 2016 Jul;97(1):55-62. doi: 10.1111/ejh.12683. Epub 2015 Oct 7.
9
Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.吉妥单抗奥唑米星用于初治急性髓系白血病儿童和青少年可通过降低复发风险提高无事件生存期：儿童肿瘤学组III期随机试验AAML0531的结果
J Clin Oncol. 2014 Sep 20;32(27):3021-32. doi: 10.1200/JCO.2014.55.3628.
10
Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.优化年轻急性髓细胞白血病患者的化疗：英国医学研究理事会 AML15 试验的结果。
J Clin Oncol. 2013 Sep 20;31(27):3360-8. doi: 10.1200/JCO.2012.47.4874. Epub 2013 Aug 12.
Zotero 插件